PuSH - Publication Server of Helmholtz Zentrum München: Finerenone and clinical outcomes in chronic kidney disease and type 2 diabetes by frailty Iidex: FIDELITY post hoc analysis.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Rossing, P.* ; Birkenfeld, A.L. ; Fioretto, P.* ; McGill, J.B.* ; Anker, S.D.* ; Pitt, B.* ; Rohwedder, K.* ; Scalise, A.* ; Scott, C.* ; Filippatos, G.*

Finerenone and clinical outcomes in chronic kidney disease and type 2 diabetes by frailty Iidex: FIDELITY post hoc analysis.

Clin. J. Am. Soc. Nephrol. 20, 968-977 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Hybrid

Abstract
Metrics
Extra information

INTRODUCTION: Frailty is associated with a higher risk of adverse outcomes. It is believed that people with a higher frailty index may be less tolerant to new treatments, often leading to inappropriate prescribing. This post hoc analysis of FIDELITY, a prespecified, pooled analysis of the FIDELIO-DKD and FIGARO-DKD phase 3 clinical trials, investigated the efficacy and safety of finerenone versus placebo according to baseline frailty index. METHODS: Between September 2015 and October 2018, 12,990 people with chronic kidney disease (CKD) and type 2 diabetes (T2D) receiving the maximum tolerated dose of a renin-angiotensin system inhibitor were randomized to receive finerenone 10 or 20 mg once daily or placebo. Baseline frailty index was calculated using the Rockwood cumulative deficit approach including 30 clinical characteristics. Primary efficacy outcomes included a kidney (kidney failure, sustained decrease of ≥57% in estimated glomerular filtration rate [eGFR], or kidney-related death) and a cardiovascular (CV) composite outcome (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). Changes in urine albumin-to-creatinine ratio (UACR) and eGFR were measured across the study period. RESULTS: Overall, kidney and CV event rates increased with increasing frailty. Finerenone reduced the risk of primary kidney and CV composite outcomes irrespective of baseline frailty (P interaction=0.93 and 0.35, respectively). Compared with placebo, finerenone also demonstrated significant reductions in UACR across all frailty subgroups (P<0.01 for all visits) and significant attenuation of eGFR decline from baseline to month 48 in the three most frail quartiles (>Q1 to ≤Q2, P=0.001; >Q2 to ≤Q3, P<0.001; >Q3, P<0.001, respectively). The incidence of serious adverse events and hyperkalemia increased with increasing frailty in both treatment arms. CONCLUSION: Finerenone reduced the risk of CV and kidney events in people with CKD and T2D versus placebo irrespective of baseline frailty status. REGISTRATION: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049).

Impact Factor

Scopus SNIP

Altmetric

7.100

0.000